Generic Symbravo Availability
Last updated on May 7, 2025.
Symbravo is a brand name of meloxicam/rizatriptan, approved by the FDA in the following formulation(s):
SYMBRAVO (meloxicam; rizatriptan benzoate - tablet;oral)
-
Manufacturer: AXSOME
Approval date: January 30, 2025
Strength(s): 20MG;EQ 10MG BASE [RLD]
Is there a generic version of Symbravo available?
No. There is currently no therapeutically equivalent version of Symbravo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symbravo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical compositions comprising meloxicam
Patent 10,029,010
Issued: July 24, 2018
Inventor(s): Tabuteau; Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,058,614
Issued: August 28, 2018
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,137,131
Issued: November 27, 2018
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,195,278
Issued: February 5, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,265,324
Issued: April 23, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,363,312
Issued: July 30, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,369,224
Issued: August 6, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,426,839
Issued: October 1, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,463,736
Issued: November 5, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,471,014
Issued: November 12, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the drug for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,471,069
Issued: November 12, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,512,692
Issued: December 24, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,512,693
Issued: December 24, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,517,950
Issued: December 31, 2019
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,532,101
Issued: January 14, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,537,642
Issued: January 21, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,561,664
Issued: February 18, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,583,144
Issued: March 10, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,653,777
Issued: May 19, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Combination treatment for migraine and other pain
Patent 10,688,102
Issued: June 23, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,688,185
Issued: June 23, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,695,429
Issued: June 30, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,695,430
Issued: June 30, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,702,535
Issued: July 7, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, allodynia, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, allodynia, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine, allodynia. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,702,602
Issued: July 7, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,722,583
Issued: July 28, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,729,696
Issued: August 4, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,729,697
Issued: August 4, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,729,773
Issued: August 4, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,758,617
Issued: September 1, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,758,618
Issued: September 1, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,780,165
Issued: September 22, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,780,166
Issued: September 22, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,799,588
Issued: October 13, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,821,181
Issued: November 3, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,821,182
Issued: November 3, 2020
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,894,053
Issued: January 19, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,905,693
Issued: February 2, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,918,722
Issued: February 16, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,933,136
Issued: March 2, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,933,137
Issued: March 2, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,940,153
Issued: March 9, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 10,987,358
Issued: April 27, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,013,805
Issued: May 25, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,013,806
Issued: May 25, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,020,483
Issued: June 1, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,045,549
Issued: June 29, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,135,295
Issued: October 5, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,207,328
Issued: December 28, 2021
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,219,626
Issued: January 11, 2022
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,285,213
Issued: March 29, 2022
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,331,323
Issued: May 17, 2022
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,369,684
Issued: June 28, 2022
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,426,414
Issued: August 30, 2022
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,471,464
Issued: October 18, 2022
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,471,465
Issued: October 18, 2022
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,504,429
Issued: November 22, 2022
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,510,927
Issued: November 29, 2022
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,571,428
Issued: February 7, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,602,563
Issued: March 14, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,607,456
Issued: March 21, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,617,755
Issued: April 4, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,617,756
Issued: April 4, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,617,791
Issued: April 4, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,628,173
Issued: April 18, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,712,441
Issued: August 1, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,738,085
Issued: August 29, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,759,522
Issued: September 19, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,801,250
Issued: October 31, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,806,354
Issued: November 7, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,826,370
Issued: November 28, 2023
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 11,865,117
Issued: January 9, 2024
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- April 11, 2036✓
- April 11, 2036
-
Pharmaceutical compositions comprising meloxicam
Patent 12,128,052
Issued: October 29, 2024
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.
Patent expiration dates:
- May 28, 2040✓
- May 28, 2040
-
Pharmaceutical compositions comprising meloxicam
Patent 9,821,075
Issued: November 21, 2017
Inventor(s): Tabuteau; Herriot
Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Patent expiration dates:
- April 11, 2036✓✓
- April 11, 2036
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- January 30, 2028 - NEW PRODUCT
More about Symbravo (meloxicam / rizatriptan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antimigraine agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
